Inhibition of endopeptidase EC 3.4.24.11 by candoxatril lowered blood pressure and increased urinary but not plasma atrial natriuretic peptide in essential hypertension.
Tunny
T J
TJ
Endocrine-Hypertension Research Unit, Greenslopes Hospital, Brisbane, Australia.
Ziesak
M D
MD
Armstrong
R
R
Klemm
S A
SA
Stowasser
M
M
Finn
W L
WL
Gordon
R D
RD
D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D009320:Atrial Natriuretic Factor / Q000097:blood / Q000652:urine; D001794:Blood Pressure / Q000187:drug effects; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D007189:Indans / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D015260:Neprilysin / Q000037:antagonists & inhibitors*; D011422:Propionates / Q000627:therapeutic use*
D000959:Antihypertensive Agents; D007189:Indans; D011422:Propionates; D009320:Atrial Natriuretic Factor; C062766:candoxatril; D015260:Neprilysin